| HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation N Chomont, M El-Far, P Ancuta, L Trautmann, FA Procopio, ... Nature medicine 15 (8), 893-900, 2009 | 1929 | 2009 |
| Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction L Trautmann, L Janbazian, N Chomont, EA Said, S Gimmig, B Bessette, ... Nature medicine 12 (10), 1198-1202, 2006 | 1913 | 2006 |
| Antiretroviral-drug resistance among patients recently infected with HIV SJ Little, S Holte, JP Routy, ES Daar, M Markowitz, AC Collier, RA Koup, ... New England Journal of Medicine 347 (6), 385-394, 2002 | 1560 | 2002 |
| High rates of forward transmission events after acute/early HIV-1 infection BG Brenner, M Roger, JP Routy, D Moisi, M Ntemgwa, C Matte, JG Baril, ... The Journal of infectious diseases 195 (7), 951-959, 2007 | 879 | 2007 |
| Towards an HIV cure: a global scientific strategy Nature reviews Immunology 12 (8), 607-614, 2012 | 605 | 2012 |
| Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection EA Said, FP Dupuy, L Trautmann, Y Zhang, Y Shi, M El-Far, BJ Hill, ... Nature medicine 16 (4), 452-459, 2010 | 579 | 2010 |
| HIV-1 Viremia Prevents the Establishment of Interleukin 2–producing HIV-specific Memory CD4+ T Cells Endowed with Proliferative Capacity SA Younes, B Yassine-Diab, AR Dumont, MR Boulassel, Z Grossman, ... The Journal of experimental medicine 198 (12), 1909-1922, 2003 | 548 | 2003 |
| Interleukin-2 therapy in patients with HIV infection INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee New England Journal of Medicine 361 (16), 1548-1559, 2009 | 426 | 2009 |
| Peripheral blood CCR4+ CCR6+ and CXCR3+ CCR6+ CD4+ T cells are highly permissive to HIV-1 infection A Gosselin, P Monteiro, N Chomont, F Diaz-Griffero, EA Said, S Fonseca, ... The Journal of Immunology 184 (3), 1604-1616, 2010 | 367 | 2010 |
| HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation ML Dion, JF Poulin, R Bordi, M Sylvestre, R Corsini, N Kettaf, A Dalloul, ... Immunity 21 (6), 757-768, 2004 | 321 | 2004 |
| Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells H Streeck, JS Jolin, Y Qi, B Yassine-Diab, RC Johnson, DS Kwon, ... Journal of virology 83 (15), 7641-7648, 2009 | 270 | 2009 |
| Wide variation in the multiplicity of HIV-1 infection among injection drug users KJ Bar, H Li, A Chamberland, C Tremblay, JP Routy, T Grayson, C Sun, ... Journal of virology 84 (12), 6241-6247, 2010 | 269 | 2010 |
| Interleukin-7 promotes HIV persistence during antiretroviral therapy C Vandergeeten, R Fromentin, S DaFonseca, MB Lawani, I Sereti, ... Blood, The Journal of the American Society of Hematology 121 (21), 4321-4329, 2013 | 266 | 2013 |
| CD4: CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV‐positive patients W Lu, V Mehraj, K Vyboh, W Cao, T Li, JP Routy African Journal of Reproduction and Gynaecological Endoscopy 18 (1), 2015 | 265 | 2015 |
| Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection BG Brenner, JP Routy, M Petrella, D Moisi, M Oliveira, M Detorio, B Spira, ... Journal of virology 76 (4), 1753-1761, 2002 | 264 | 2002 |
| Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells S Reiss, AE Baxter, KM Cirelli, JM Dan, A Morou, A Daigneault, ... PloS one 12 (10), e0186998, 2017 | 261 | 2017 |
| Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of … J Van Wyk, F Ajana, F Bisshop, S De Wit, O Osiyemi, J Portilla Sogorb, ... Clinical Infectious Diseases 71 (8), 1920-1929, 2020 | 251 | 2020 |
| Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized … Y Levy, I Sereti, G Tambussi, JP Routy, JD Lelievre, JF Delfraissy, ... Clinical infectious diseases 55 (2), 291-300, 2012 | 240 | 2012 |
| Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo CC Nixon, M Mavigner, GC Sampey, AD Brooks, RA Spagnuolo, ... Nature 578 (7793), 160-165, 2020 | 236 | 2020 |
| Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use H Salomon, MA Wainberg, B Brenner, Y Quan, D Rouleau, P Coté, ... Aids 14 (2), F17-F23, 2000 | 233 | 2000 |
